Floatz logo

Clindamycin

Bacterial Infectious Disease

Phillip Brian SmithSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Bacterial Infectious Disease cohort.

Asset / SponsorPhaseRating
NORMAL HUMAN SERUM ALBUMIN
EASL - CLIF Consortium
Phase 4BB
L-Ofloxacin
Children's Oncology Group
Phase 3BB
Xembify
Grifols Therapeutics LLC
Phase 3B
Mucoid Exopolysaccharide P. Aeruginosa Immune Globulin Iv
National Center for Research Resources (NCRR)
Phase 2B

Same molecule, other indications

Clindamycin is also rated in:

RashDormant
B
Indicative ·
57 / 100
View asset →
head and neck cancerDormant
CCC
Indicative ·
54 / 100
View asset →
toxic dermatosisDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →